TTK Healthcare Limited , a prominent player in the healthcare sector, has reported a mixed set of financial results for the second quarter of the fiscal year. The company saw an increase in net profit but faced challenges in terms of EBITDA performance.

Key Financial Highlights

Profit Growth Amidst Challenges

TTK Healthcare demonstrated resilience in its bottom line, reporting a net profit of ₹204.00 crore for Q2, up from ₹172.00 crore in the same period last year, marking an 18.60% increase. This growth in profit is particularly noteworthy given the challenging operating environment.

Revenue Performance

The company's revenue saw a marginal increase, growing to ₹2,000.00 crore from ₹1,980.00 crore year-over-year. This modest 1.00% growth suggests a relatively stable demand for the company's products and services in the market.

EBITDA and Margin Pressure

Despite the growth in revenue and net profit, TTK Healthcare faced significant pressure on its operational efficiency. The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) declined to ₹53.30 crore from ₹82.30 crore in the previous year. This represents a substantial decrease of 35.20%.

More concerning is the compression in the EBITDA margin, which fell to 2.62% from 4.15% in the same quarter last year. This 153 basis points reduction in margin indicates increased operational costs or pricing pressures in the market.

Analysis and Outlook

The divergence between net profit growth and EBITDA decline suggests that TTK Healthcare might have benefited from non-operational factors such as lower tax outgo or exceptional items. The company's ability to maintain profit growth despite margin pressures demonstrates effective cost management in other areas.

However, the significant drop in EBITDA and margin compression warrants attention. It may indicate rising input costs, increased competition, or challenges in pricing power. The management may need to focus on operational efficiency and cost control measures to improve margins in the coming quarters.

As TTK Healthcare navigates through these mixed results, investors and analysts will be keen to see how the company addresses the operational challenges while maintaining its profit growth trajectory in the future quarters.

TTK Healthcare Limited has completed the transmission of shares from two deceased promoters to their legal heirs, marking the conclusion of a regulatory process that began following the deaths of key promoter group members.

Share Transmission Details

The company announced on December 29, 2025, that it has received intimation regarding the transmission of equity shares held by the deceased promoters. The transmission involves a total of 7,73,298 shares being transferred to three legal heirs:

*Minor represented by her mother and natural guardian Mrs. Maitri Gopalakrishna

Regulatory Compliance and Classification Changes

Following the transmission, TTK Healthcare has made several regulatory disclosures under SEBI LODR Regulations. Ms. Sarayu Thiruvallur Thattai will now be classified as a person belonging to the Promoter Group in accordance with Regulation 31A(6)(a).

Under Regulation 31A(6)(c), both Late Thiruvallur Thattai Jagannathan and Late Thiruvallur Thattai Venkatesh will cease to be classified as Promoter and Promoter Group members, respectively.

Updated Shareholding Pattern

The company has confirmed that the updated and accurate Promoter and Promoter Group shareholding will be reflected in the Shareholding Pattern for the quarter ending December 31, 2025. This transmission process ensures continuity in the company's ownership structure while maintaining compliance with regulatory requirements.

The completion of this transmission process represents a significant milestone in TTK Healthcare's corporate governance, providing clarity on the promoter group composition following the earlier announced deaths of the promoter group members.